Slide 1: Second quarter 2022 results
Audiocast presentation 15 July 2022 Q2 Second quarter 2022 results
Slide 2: Forward looking statements
2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-lo
Slide 3: Agenda
3 Agenda • Introduction and Q2 highlights Company participants • Financial performance Fredrik Tiberg, PhD • Commercial update President & CEO, Head R&D • R&D pipeline development Jon Garay Alonso Chief Financial Officer • Key take-aways Richard Jameson • Q&A Chief Commercial Officer
Slide 4: Emerging leader in opioid dependence treatment
4 Emerging leader in opioid dependence treatment Advancing late-stage pipeline with blockbuster potential Strong revenue growth towards sustained profitability
Slide 5: Camurus' second quarter highlights
5 Camurus’ second quarter highlights Profitable in Q2 and H1 Commercialization execution Progress in the pipeline Continued high double-digit YoY Increased patient shares and Variation applications for Buvidal revenue growth expanded our markets to include treatment of chronic pain Strong ca
Slide 6: Financial performance
camurus Financial performance
Slide 7: High growth resulted in profitability
7 High growth resulted in profitability Revenue Operating Result Revenue growth MSEK MSEK +65% vs Q2 2021 500 50 447 Improved result 400 7 12 +67 MSEK vs Q2 2021 0 +69% +67 MSEK 300 -23 Cash position 264 +98 MSEK 227 -50 SEK 428 million Q2 200 -60 +1% vs Q2 2021 +65% 130 137 -86 -100 100 76 -100 0 -
Slide 8: Reported profit and loss and FY 2022 outlook
8 Reported profit and loss and FY 2022 outlook CER MSEK Apr – Jun Change Change 2022 vs. 2021 vs. 2021 Raised FY 2022 outlook2 Total revenues 226.7 +64% +56% Total revenue1 SEK 900 to 950 million Gross margin 201.6 +38.8 bps +265 bps (same as previously) Product sales1 OPEX -195.7 +10% +6% SEK 875 t
Slide 9: Commercial update
Camurus Commercial update
Slide 10: Buvidal sales growth underscores potential
10 Buvidal sales growth underscores potential •12th consecutive quarter of double-digit Q-on-Q growth •Quarterly product sales ‒ SEK 225 million sales (+65% vs. Q2 2021, +11% vs. Q1 2022) MSEK ‒ Est. close to 30,000 patients in treatment at the end of Q2 250 2020 2021 2022 225 •Strengthening market
Slide 11: Continued focus on commercial execution
11 Continued focus on commercial execution •Launched – full access ‒ Facilitating patient uptake • Educating on informed choice and the growing scientific evidence • Ensuring Buvidal offered as a first line treatment option •Launched – some restrictions on access ‒ Addressing funding needs and barri
Slide 12: Regulatory processes provide further growth potential
12 Regulatory processes provide further growth potential Brixadi™ tentatively approved in the US Market authorization processes in MENA ‒ Braeburn issued with new Complete Response ‒ Seven MAA applications under review in MENA Letter (CRL) for the Brixadi NDA on 15 Dec 2021 Approval decisions expe
Slide 13: High visibility at scientific conferences 2022
13 High visibility at scientific conferences 2022 Q1 Q2 Q3 Q4 ASAM CPDD ISAM Global 31 Mar-3 Apr 11-15 Jun 4-7 Oct Hollywood, FL, Minneapolis, MN, USA USA Valletta, Malta IOTOD ALBATROS Nordic Add. Lisbon European 11-12 May 8-10 Jun Sym posium Addictions 22-23 Sep 24-25 Nov Virtual Paris, France Upp
Slide 14: R&D pipeline developments
14 R&D pipeline developments
Slide 15: Broad and diversified pipeline for sustainable growth
15 Broad and diversified pipeline for sustainable growth Phase 1 Phase 2 Phase 3 Registration CAM2043 CAM2029 CAM2029 Brixadi™ Pulmonary arterial Polycystic liver disease Acromegaly Opioid use disorder (US)1 hypertension CAM2047 CAM2032 CAM2029 Buvidal® Chemotherapy-induced Prostate cancer Gastroent
Slide 16: Octreotide SC depot – CAM2029
16 Octreotide SC depot – CAM2029 Three registration programs in rare disease indications Market potential ‒ Acromegaly (ACRO), gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD) CAM2029 peak market sales estimate in acromegaly, NET, CAM2029 has favorable prope
Slide 17: CAM2029 – comprehensive clinical programs in three indications
17 CAM2029 – comprehensive clinical programs in three indications ACRO Phase 3 RCT Four completed clinical trials ACRO Phase 3 LST characterizing PK, PD in healthy subjects GEP-NET Phase 3 RCT ”SORENTO” Extension and patients (N=249) PLD Phase 2b RCT ”POSITANO” OLE Prefilled pen PK bridge - 2021 202
Slide 18: POSITANO Phase 2b study in PLD
18 “POSITANO” Phase 2b study in PLD (HS-20-677) •Study design •Primary endpoint ‒ A randomized, placebo-controlled, double-blind, multi- ‒ Change from baseline to Week 53 in height-adjusted center trial to assess efficacy and safety of CAM2029 in total liver volume (htTLV) patients with symptomatic
Slide 19: CAM2029 status and expected milestones
19 CAM2029 status and expected milestones •Acromegaly •Polycystic liver disease (PLD) Two phase 3 studies ongoing IND safe to proceed letter Orphan drug designation in the EU Orphan Drug Designation (US) Target completion of recruitment Sept./Oct. 2022 PRO developed and aligned with FDA
Slide 20: Topline results from CAM2043 Phase 2 in Raynaud's Phenomenon
20 Topline results from CAM2043 Phase 2 in Raynaud’s Phenomenon •Explorative Phase 2 study of weekly SC treprostinil in patients with Raynaud’s Phenomenon secondary to systemic sclerosis ‒ The primary endpoint of statistically significant effect on finger temperatures after cold challenge 6 h post-d
Slide 21: Welcome to Camurus' Capital Markets and R&D Day 2022
21 Welcome to Camurus’ Capital Markets and R&D Day 2022 When: Tuesday 6 September, 1 – 5 pm Where: IVA Conference Center, Grev Turegatan 16, Stockholm During the event, members of Camurus’ senior management will provide an update on the company strategy, business progress and key R&D pipeline progra
Slide 22: Key takeaways Q2 2022
22 Key takeaways Q2 2022 Profitability reached in the quarter and first half of the year Strong commercial execution R&D pipeline progress towards new approvals Full year 2022 result guidance raised
Slide 23: Q&A
O&A Camurus
Slide 24: Recent and expected news flow 2022/23
24 Recent and expected news flow 2022/23 H1 2022 H2 2022 2023 First dosing in Ph. 3 switch Divestment of episil® oral liquid Completed enrollment in CAM2029 study of CAM4072 (Rhythm) to Solasia SORENTO Phase 3 NET Buvidal chronic pain label Topline Phase 2 results for Phase 3 RCT results
Slide 25: Key figures second quarter 2022
25 Key figures second quarter 2022 MSEK Apr – Jun Apr – Jun Change Jan – Jun Jan – Jun Change Jan – Dec 2022 2021 2022 2021 2021 Total revenues 227 138 +64% 447 264 +69% 601 whereof product sales 225 137 +65% 427 261 +64% 594 Operating expenses 196 179 +10% 384 315 +22% 628 Operating result 7 -60 N/
Slide 26: Experienced and committed management team
26 Experienced and committed management team Fredrik Tiberg, PhD Education: M.Sc. in Chemical Engineering, Lund Institute of Jon Garay Alonso Education: Bachelor in Business Administration by President & CEO, Head R&D Technology, PhD and Assoc. Prof. Physical Chemistry, Lund Chief Financial Officer
Slide 27: Shareholders and analyst coverage
27 Shareholders and analyst coverage Shareholders as of 30 June 2022 Number of shares % of capital % of votes Sandberg Development AB 21,875,692 39.9 39.9 Fjärde AP-fonden 3,502,450 6.4 6.4 Avanza Pension 2,712,571 4.9 4.9 Analysts Didner & Gerge Fonder 2,572,977 4.7 4.7 Carnegie Fredrik Tiberg, CEO